Category Archives: IP

J.P. Morgan: Pharma's Agenda for 2014

Presenters at the 32nd annual J.P. Morgan Healthcare Conference talked up value-based pricing, emerging market strategies, complex generics and new technology, from bedside devices and genetic sequencers to first-in-class mechanisms of action. Company executives honed in on their chosen therapeutic areas and made the case for aggressive spending in R&D to bring the next generation […]
Also posted in Biotech, Corporate Responsibility, Deals, Emerging Markets, Europe, Events, FDA, Gene therapy, Global, leadership, Legal, Manufacturing, Market Access, Orphan Drugs, People, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

Best of the Blog: PharmExec's 10 Most Read Stories in 2013

Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. For our colleagues in the Northeast bracing for yet another snow storm – and for those of you with better short-term environmental prospects – here are the 10 most-read stories published on PharmExec‘s blog during 2013, in case you […]
Also posted in Advertising, Biotech, Emerging Markets, Europe, FDA, Global, Guest Blog, healthcare, Legal, Market Access, People, pricing, R&D, Regulatory, Strategy, Technology | Tagged , , , , , , , , , , , , , | Leave a comment

Does IP Stimulate Growth and Create Jobs? New European Data Says Yes

A new study shows the importance of intellectual property in stimulating jobs and productivity in the EU. Surprisingly, it illustrates pharma’s established position as an IP powerhouse, evidence that adds conviction to the views expressed by GSK CEO Andrew Witty and other industry leaders that growing cuts on drug pricing are limiting an industry that […]
Also posted in Europe | Tagged , , , , , , , , | 1 Comment

There's New Hustle in Myeloma

The Multiple Myeloma Research Foundation (MMRF) has launched a new initiative to increase the pace of innovation in myeloma research through faster cures and more efficient, timely trials for patients. Founded in 1998, MMRF is the leading non-profit organization in the myeloma space, dedicating 90 per cent of its funding to medical research, disease awareness […]
Also posted in Events, FDA, R&D | Tagged , , , , , , | Leave a comment

Roche Jumps into Medicines Patent Pool with Pricing and Licensing Deal

Roche this week has announced a partnership with the UN-backed Medicines Patent Pool (MPP) to provide its drug valganciclovir, better known in the developed world as Valcyte, in 138 countries for a reduced price. In addition to making the drug available in these markets for up to 90% cheaper than current price, Roche has decided […]
Also posted in Corporate Responsibility, Deals, Emerging Markets, Global, Market Access, pricing | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta